Colgate-Palmolive (CL)

Total Costs & Expenses

$16.70B

TTM · Period ending: · USD

CL logo

CL Total Costs & Expenses

Latest reported$16.70B
CL TTM Total Costs & Expenses (-$4.65B → $16.70B)
High-resolution chart · PNG

CL total costs & expenses history

Trailing twelve months (TTM) · USD. Each value covers four complete reported quarters.

Colgate-Palmolive Total Costs & Expenses — Trailing twelve months (TTM) (USD)
Period endingTotal Costs & Expenses (USD)
16,700,000,000
16,385,000,000
16,052,000,000
15,753,000,000
15,642,000,000
15,512,000,000
15,565,000,000
15,521,000,000
15,450,000,000
15,331,000,000
15,260,000,000
15,141,000,000
14,831,000,000
14,630,000,000
14,223,000,000
13,976,000,000
13,859,000,000
13,547,000,000
13,446,000,000
13,316,000,000
13,023,000,000
12,683,000,000
12,475,000,000
12,219,000,000
12,098,000,000
12,089,000,000
11,935,000,000
11,747,000,000
11,664,000,000
11,613,000,000
11,647,000,000
11,635,000,000
11,685,000,000
11,613,000,000
11,455,000,000
11,286,000,000
11,152,000,000
11,257,000,000
11,329,000,000
11,571,000,000
11,590,000,000
11,823,000,000
12,138,000,000
11,877,000,000
12,445,000,000
12,683,000,000
13,164,000,000
13,568,000,000
13,519,000,000
13,587,000,000
13,469,000,000
13,693,000,000
13,615,000,000
13,460,000,000
13,149,000,000
13,100,000,000
13,144,000,000
13,076,000,000
12,893,000,000
12,717,000,000
12,354,000,000
12,003,000,000
12,075,000,000
12,092,000,000
12,179,000,000
12,170,900,000
11,711,300,000
11,523,800,000
11,671,400,000
12,011,300,000
12,309,200,000
12,317,700,000
11,957,500,000
11,507,500,000
11,081,000,000
10,593,300,000
10,328,200,000
10,133,800,000
9,924,100,000
9,828,400,000
9,541,600,000
9,284,600,000
9,181,900,000
9,121,200,000
8,971,700,000
8,662,200,000
8,394,000,000
8,077,700,000
7,908,200,000
7,822,400,000
7,678,100,000
7,627,400,000
7,506,500,000
7,384,600,000
7,281,200,000
7,320,900,000
7,369,100,000
7,449,900,000
7,566,500,000
7,603,300,000
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.